Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POG randomized supportive care pathway study for older adults with cancer receiving oral anticancer therapy
2025-523610-83-00Phase 4Authorised
- Sponsor
- Gustave Roussy
- Start
- Sep 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abemaciclib, ribociclib, palbociclib, everolimus, alectinib and 13 more in breast cancer, bronchial carcinoma, prostate cancer (PCa) and 4 more (2 arms), sponsored by Gustave Roussy. Primary endpoint: Rate of subjects with severe treatment-related adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
abemaciclibribociclibpalbociclibeverolimusalectinib
03
Conditions
breast cancerbronchial carcinomaprostate cancer (PCa)colorectal cancer (CRC)kidney cancer
Beyond the preview
Go deeper on 2025-523610-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523610-83-00.